FGFR1OP2
FGFR1OP2 (FGFR1 oncogene partner 2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
May be involved in wound healing pathway. Location: Cytoplasm (UniProt). Locus 12p11.23 (HGNC).
- Leukaemia: Open Targets association 0.55 with leukaemia (MONDO_0005059)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"FGFR1OP2" OR ABSTRACT:"FGFR1OP2" OR TITLE:"FGFR1 oncogene partner 2" OR ABSTRACT:"FGFR1 oncogene partner 2" OR TITLE:"DKFZp564O1863" OR ABSTRACT:"DKFZp564O1863") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGFR1OP2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/fgfr1op2.json. Licence CC BY-NC 4.0.